Other and unspecified immunodeficiencies with predominantly antibody defects

DOID MESH PheWeb

D3_IMMUDEFANTIBODYNAS

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 D80.8, D80.9

Hospital discharge: ICD-9 2790C|2790X

Hospital discharge: ICD-8 $!$

Cause of death: ICD-10 D80.8, D80.9

Cause of death: ICD-9 2790C|2790X

Cause of death: ICD-8 $!$

258

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

258

Check minimum number of events None

258

Include endpoints None

258

D3_IMMUDEFANTIBODYNAS

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Other and unspecified immunodeficiencies with predominantly antibody defects based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

248

159

Unadjusted prevalence (%)

0.08

0.09

0.07

Mean age at first event (years)

47.22

48.90

44.22

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: D3_IMMUDEFANTIBODYNAS – Other and unspecified immunodeficiencies with predominantly antibody defects
GWS hits: 1

Survival analyses between endpoints

↥

Plot

before Other and unspecified immunodeficiencies with predominantly antibody defects
after Other and unspecified immunodeficiencies with predominantly antibody defects

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Other and unspecified immunodeficiencies with predominantly antibody defects

↥